UCB 将来の成長
Future 基準チェック /36
UCB利益と収益がそれぞれ年間17.3%と9.7%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に19.3% 17.6%なると予測されています。
主要情報
17.3%
収益成長率
17.62%
EPS成長率
| Pharmaceuticals 収益成長 | 10.6% |
| 収益成長率 | 9.7% |
| 将来の株主資本利益率 | 19.35% |
| アナリストカバレッジ | Good |
| 最終更新日 | 15 May 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブの更新 • May 15
UCB: Epilepsy Blockbusters And Neuroscience Pipeline Will Drive Future Upside Potential
Analysts have nudged their average price target for UCB higher, with fair value moving from €284.65 to about €288.21 as they factor in updated assumptions on discount rate, revenue growth, profit margins, and future P/E, supported by recent target hikes and fresh Outperform ratings on the stock. Analyst Commentary Recent research points to a split but constructive view on UCB, with several firms adjusting ratings and targets as they reassess the stock's risk and reward profile.
ナラティブの更新 • Apr 30
UCB: Epilepsy Portfolio Execution To Drive Future Earnings Power Upside
The analyst fair value estimate for UCB has shifted from €310 to €340, reflecting updated assumptions on revenue growth, higher projected profit margins, a slightly adjusted discount rate, a revised future P/E, and recent Street research in which analysts highlight UCB's epilepsy portfolio and reset price targets in the €300 to €340 range. Analyst Commentary Recent Street research on UCB has been mixed, with some caution on near-term risk and reward but also clear pockets of optimism tied to its neuroscience and epilepsy franchises.ナラティブの更新 • Apr 16
UCB: Epilepsy And Neuroscience Execution Will Shape Balanced Risk Reward Profile
Analysts have adjusted the UCB price target toward €285, reflecting a blend of more cautious views that see risk and reward as balanced around €260 and more optimistic calls pointing toward €304 to €340, supported by expectations for its epilepsy portfolio and broader neuroscience exposure. Analyst Commentary Bullish Takeaways Bullish analysts see upside toward €304 to €340, suggesting that current pricing does not fully reflect expectations around the epilepsy portfolio and broader neuroscience pipeline.ナラティブの更新 • Apr 01
UCB: Epilepsy Franchise And Dermatology Data Will Shape Future Risk Reward Balance
Narrative Update on UCB The analyst price target for UCB has been adjusted slightly lower to about €285. This reflects a blend of more cautious views that see a balanced risk and reward at current levels, and more optimistic targets that highlight UCB's epilepsy portfolio and recent upward revisions from several banks.ナラティブの更新 • Mar 18
UCB: Epilepsy And Psoriatic Arthritis Execution Will Shape Future Risk Reward Balance
The updated analyst price target for UCB moves to €284.85 from €275.74. This reflects a mix of more conservative revenue growth assumptions, higher expected profit margins, and a lower future P/E multiple, in line with recent research that balances enthusiasm around epilepsy assets with a more measured view on risk and reward.
ナラティブの更新 • Mar 04
UCB: Epilepsy Franchise Expectations Will Eventually Strain Current Share Price
We are lifting our fair value estimate for UCB from €173.07 to €209.22, reflecting higher assumed revenue growth and profit margins as analysts highlight a stronger outlook for the epilepsy franchise and raise price targets into the €300+ range. Analyst Commentary Recent Street research on UCB has centered on the epilepsy franchise and the broader neuroscience portfolio, with several firms updating their views and price targets.ナラティブの更新 • Feb 18
UCB: Epilepsy Pipeline Progress And Execution Will Shape Future Upside Balance
Our Analyst Price Target for UCB has moved higher from €261.42 to €275.74, reflecting analysts' updated assumptions on revenue growth, profitability and P/E in light of recent Street target lifts to around €304 to €310. Analyst Commentary Recent Street research on UCB has centered on higher price targets, with bullish analysts adjusting their views to reflect updated assumptions on revenue, profitability and P/E.ナラティブの更新 • Feb 04
UCB: Future Earnings Power To Reflect Rare Disease And Epilepsy Execution
Analysts have raised their price target on UCB to €310 from €270, citing updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple as the main drivers of the change. Analyst Commentary Recent commentary from bullish analysts has centered on higher valuation support for UCB, with the new €310 price target used as a reference point for what they see as stronger execution and earnings potential than previously modeled.ナラティブの更新 • Jan 21
UCB: Late-Stage Pipeline And Margin Execution Will Shape Balanced Upside Potential
Analysts raised their price target on UCB to €310 from €270, citing updated expectations for slightly stronger revenue growth, improved profit margins, and a modestly lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher €310 target as a sign that they see current valuation as not fully reflecting updated revenue and margin expectations.ナラティブの更新 • Jan 07
UCB: Raising Future Fair Value On Strengthening Rare Disease And Epilepsy Franchise
Analysts have raised their fair value estimate for UCB from €255 to €310, citing recent price target increases from the Street and updated assumptions on revenue growth, profit margins and future P/E levels. Analyst Commentary Bullish analysts have recently adjusted their views on UCB, with fresh price targets that now cluster around €290 to €310.ナラティブの更新 • Dec 18
UCB: Expanding Late-Stage Pipeline And New Launches Will Drive Future Upside
UCB's analyst price target has been raised from EUR 258.33 to EUR 264.67 as analysts factor in slightly stronger revenue growth expectations, despite a modestly lower projected profit margin and only a small uptick in future valuation multiples. Analyst Commentary Recent price target increases signal that bullish analysts see a more attractive risk reward profile for UCB, driven by improving growth visibility and confidence in execution.ナラティブの更新 • Dec 04
UCB: Pipeline Execution And New Launches Will Support Balanced Future Upside Potential
UCB's fair value estimate has been nudged higher to approximately EUR 258 from EUR 257, reflecting analysts' upward revisions to price targets, with recent moves to EUR 240, EUR 285 and EUR 290. These changes highlight confidence in the company's earnings trajectory despite slightly softer margin and growth assumptions.ナラティブの更新 • Nov 20
UCB: Recent Pipeline Advances And Margin Strength Will Drive Share Price Higher
Analysts have slightly raised their fair value estimate for UCB to €256.67. They cite recent upward revisions to price targets, supported by continued expectations for stable profit margins and healthy revenue growth.分析記事 • Nov 11
UCB (EBR:UCB) Could Easily Take On More Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...ナラティブの更新 • Nov 06
UCB: Strong Profit Margins And Momentum Will Drive Shares Higher
UCB's fair value estimate has increased by approximately EUR 4.50, as analysts highlight robust performance and upward revisions to price targets. This follows renewed confidence in the company’s profit margin outlook.ナラティブの更新 • Oct 22
Analysts Raise UCB Price Targets Amid Positive Sector Outlook and Improved Growth Forecasts
UCB's analyst price target has been raised from €240.28 to €251.11, as analysts cite upward revisions to revenue growth forecasts along with an improved sector outlook. Analyst Commentary Recent analyst actions reflect a strongly positive sentiment toward UCB's outlook, as multiple firms have revised their price targets upward and maintained favorable ratings.分析記事 • Oct 14
Market Participants Recognise UCB SA's (EBR:UCB) Earnings Pushing Shares 25% Higher
UCB SA ( EBR:UCB ) shares have continued their recent momentum with a 25% gain in the last month alone. Looking back a...ナラティブの更新 • Oct 08
Aging Populations And Emerging Markets Will Unlock Opportunity
UCB's analyst price target has been increased from €229.06 to €240.28. This change reflects improved revenue growth expectations and profit margins highlighted by recent analyst updates.ナラティブの更新 • Sep 24
Aging Populations And Emerging Markets Will Unlock Opportunity
The slight increase in UCB’s consensus price target to €229.06 reflects improved revenue growth forecasts, while profit margin expectations remain stable. What's in the News Three-year data from BE HEARD trials show sustained efficacy and quality of life improvements with BIMZELX® in moderate-to-severe hidradenitis suppurativa, with better outcomes linked to earlier treatment.ナラティブの更新 • Aug 27
Aging Populations And Emerging Markets Will Unlock Opportunity
Analysts have raised their price target for UCB to €223.17, citing robust fundamentals, resilient earnings growth, and improved confidence in management despite recent share price weakness. Analyst Commentary Recent share price pullback seen as disconnected from underlying business strength.分析記事 • Jul 17
UCB SA (EBR:UCB) Not Lagging Market On Growth Or Pricing
When close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") below 14x, you may consider UCB...
新しいナラティブ • Mar 02
BIMZELX's Successful Launch Will Expand Future Market Opportunities In Dermatology And Rheumatology
UCB's new product launches and high R&D success rate are driving anticipated revenue and margin growth across global markets.業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 10,669 | 2,828 | 3,152 | 3,685 | 16 |
| 12/31/2027 | 9,532 | 2,265 | 2,562 | 3,025 | 17 |
| 12/31/2026 | 8,457 | 1,763 | 1,943 | 2,400 | 17 |
| 12/31/2025 | 7,741 | 1,558 | 1,842 | 2,291 | N/A |
| 9/30/2025 | 7,295 | 1,445 | 1,514 | 1,934 | N/A |
| 6/30/2025 | 6,848 | 1,332 | 1,185 | 1,576 | N/A |
| 3/31/2025 | 6,500 | 1,199 | 1,053 | 1,409 | N/A |
| 12/31/2024 | 6,152 | 1,065 | 920 | 1,242 | N/A |
| 9/30/2024 | 5,803 | 653 | 745 | 1,066 | N/A |
| 6/30/2024 | 5,454 | 240 | 569 | 889 | N/A |
| 3/31/2024 | 5,318 | 292 | 507 | 825 | N/A |
| 12/31/2023 | 5,182 | 343 | 445 | 761 | N/A |
| 6/30/2023 | 5,111 | 332 | 620 | 975 | N/A |
| 3/31/2023 | 5,279 | 376 | 684 | 1,047 | N/A |
| 12/31/2022 | 5,447 | 420 | 748 | 1,119 | N/A |
| 6/30/2022 | 5,854 | 887 | 982 | 1,462 | N/A |
| 3/31/2022 | 5,816 | 971 | 1,021 | 1,508 | N/A |
| 12/31/2021 | 5,777 | 1,055 | 1,060 | 1,553 | N/A |
| 9/30/2021 | 5,647 | 996 | 907 | 1,371 | N/A |
| 6/30/2021 | 5,517 | 936 | 754 | 1,188 | N/A |
| 3/31/2021 | 5,432 | 834 | 743 | 1,135 | N/A |
| 12/31/2020 | 5,347 | 732 | 732 | 1,081 | N/A |
| 6/30/2020 | 5,198 | 743 | 706 | 908 | N/A |
| 3/31/2020 | 5,056 | 767 | 647 | 895 | N/A |
| 12/31/2019 | 4,913 | 790 | 588 | 882 | N/A |
| 6/30/2019 | 4,686 | 652 | N/A | 950 | N/A |
| 3/31/2019 | 4,659 | 722 | N/A | 1,020 | N/A |
| 12/31/2018 | 4,632 | 792 | N/A | 1,089 | N/A |
| 6/30/2018 | 4,569 | 872 | N/A | 1,092 | N/A |
| 3/31/2018 | 4,522 | 812 | N/A | 1,010 | N/A |
| 12/31/2017 | 4,474 | 752 | N/A | 927 | N/A |
| 9/30/2017 | 4,400 | 708 | N/A | N/A | N/A |
| 6/30/2017 | 4,325 | 664 | N/A | 780 | N/A |
| 3/31/2017 | 4,236 | 604 | N/A | 604 | N/A |
| 12/31/2016 | 4,147 | 543 | N/A | 427 | N/A |
| 9/30/2016 | 4,051 | 439 | N/A | N/A | N/A |
| 6/30/2016 | 3,955 | 334 | N/A | 66 | N/A |
| 3/31/2016 | 3,916 | 299 | N/A | 156 | N/A |
| 12/31/2015 | 3,876 | 264 | N/A | 246 | N/A |
| 9/30/2015 | 3,773 | 266 | N/A | 388 | N/A |
| 6/30/2015 | 3,670 | 268 | N/A | 530 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: UCBの予測収益成長率 (年間17.3% ) は 貯蓄率 ( 2.4% ) を上回っています。
収益対市場: UCBの収益 ( 17.3% ) はBelgian市場 ( 14.1% ) よりも速いペースで成長すると予測されています。
高成長収益: UCBの収益は増加すると予測されていますが、大幅には増加しません。
収益対市場: UCBの収益 ( 9.7% ) Belgian市場 ( 6.8% ) よりも速いペースで成長すると予測されています。
高い収益成長: UCBの収益 ( 9.7% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: UCBの 自己資本利益率 は、3年後には低くなると予測されています ( 19.3 %)。
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/17 22:04 |
| 終値 | 2026/05/15 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
UCB SA 17 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。40
| アナリスト | 機関 |
|---|---|
| Charles Pitman | Barclays |
| Charles Pitman | Barclays |
| Brian Bourdot | Barclays |